An international study assessing the efficacy of a new drug (S 066913) in paroxysmal atrial fibrillation

Registry ID

EUCTR2014-002333-63

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Institut de Recherches Internationales Servier

Start date

2015-01-22

Completion date

2015-09-24

Last update

2026-08-16

Conditions

• Paroxysmal Atrial Fibrillation

Summary

Evaluation of the efficacy of 3 doses of S066913 (5mg, 25mg, 100mg) versus placebo administered for 4 weeks on atrial fibrillation and/or atrial tachycardia burden in patients with paroxysmal atrial fibrillation who are potentially eligible for atrial fibrillation ablation and are implanted with insertable cardiac monitoring device.

Locations

• , , Czechia
• , , Slovakia
• , , Sweden
• , , Denmark
• , , Netherlands
• , , Poland

Related clinical trials

• A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
• Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System
• STOP AF First Post-Approval Study
• Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
• Pulmonary Vein Isolation Strategy of Very High Power Short Duration in Patients With Paroxysmal Atrial Fibrillation
• Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation

View on source registry